Before treatment, this 6-year-old’s Tanner 3 breast development, growth velocity of 9.5 cm/year, and bone age of 9 years raise concern for rapidly progressive puberty and warrant evaluation. They do not, by themselves, establish CPP; the vignette gives no gonadotropin results. The monitoring discussion below assumes that evaluation confirms CPP and the family and clinical team choose GnRH-agonist treatment.
Then comes a common follow-up question: must her LH fall into a prepubertal range at every visit to prove the treatment is working? Usually, no. The practical goal is to follow the child’s clinical trajectory and reserve hormone testing for signs that suppression may be inadequate.
Follow the child’s trajectory
Before the first dose, document the growth chart, measured height and growth velocity, Tanner stage, bone-age interpretation, and treatment formulation and schedule. Record relevant family observations and any prior exposure to sex-steroid medications. These give the team a baseline for interpreting what changes—or does not change—during treatment.
At scheduled follow-up, assess growth over a meaningful interval and compare it with the pretreatment pattern. Reassess breast development and ask about symptoms such as breast tenderness or bleeding. Breast fullness does not have to disappear for treatment to be effective; stabilization without further progression can be reassuring. Growth velocity is useful in context, but there is no need to demand a particular number at a particular month.
| Follow-up pattern | Practical interpretation |
|---|---|
| No further pubertal progression and growth no longer follows the prior accelerated pattern | Reassuring clinical response; routine LH testing is generally not needed. |
| A measurable or “pubertal-range” random LH without clinical progression | Not sufficient by itself to label treatment failure or change the dose. |
| Progressive breast development or persistent/accelerating pubertal growth | Recheck the treatment timeline and administration; consider targeted testing before changing therapy. |
Bone age adds context about skeletal maturation. Current guidance describes annual bone-age assessments as part of routine monitoring, interpreted alongside growth and pubertal staging—not as a stand-alone verdict from one film or a single bone-age-to-chronological-age ratio.
Why routine LH can mislead
Current recommendations suggest against routine LH or sex-steroid testing in children who have no clinical signs of treatment failure. A random basal LH may remain above prepubertal levels even when puberty is clinically suppressed. Stimulated LH results and sex-steroid measurements also depend on the assay, treatment formulation, and timing; a laboratory value does not automatically predict meaningful clinical escape.
This does not mean that inadequate suppression never occurs. Rather, a routine lab schedule can produce results that are hard to interpret and may prompt unnecessary blood draws or dose changes. The evidence supporting this approach is limited, and no single biochemical cutoff reliably settles every case. The important distinction is between testing a child who is progressing and testing a clinically stable child just because the calendar says it is time.
When progression raises concern
If breast development progresses or growth remains persistently pubertal, do not jump straight from one finding to a higher dose. First confirm the exact medication and dosing interval, when the last dose was given, and whether administration was complete and on schedule. Review serial heights and examinations rather than relying on a single measurement.
When the clinical course raises concern, the treating specialist may use basal or stimulated gonadotropins and sex-steroid testing to assess suppression before changing the dose, interval, or formulation. Interpret the results in light of the assay and treatment timing. If the examination and laboratory results do not fit together, reassess the diagnosis and consider other sources of sex-steroid exposure rather than reflexively escalating GnRH-agonist therapy.
Common traps
- Treating any detectable LH as failure. A measurable basal LH can occur despite adequate clinical suppression.
- Expecting breast tissue to disappear. Lack of regression alone is not the same as continued progression.
- Changing treatment on one lab result. Check the clinical trajectory, assay, timing, and medication delivery first.
- Calling bone age the “ultimate arbiter.” Use the serial trend with growth and pubertal findings; do not make one film a pass/fail test.
Practical takeaways
- Confirm CPP before applying a treatment-monitoring plan; the vignette’s clinical signs do not provide the missing hormone results.
- During therapy, follow growth velocity and Tanner stage at interval visits, and review bone age about annually.
- Routine LH and sex-steroid testing is not recommended for a clinically stable child; reserve it for suspected treatment failure.
- Before changing therapy, verify medication timing and administration, then interpret targeted test results in clinical context.
